Compare MDRR & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDRR | CMMB |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.3M | 19.9M |
| IPO Year | 2015 | 2023 |
| Metric | MDRR | CMMB |
|---|---|---|
| Price | $11.62 | $2.42 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 2.8K | ★ 112.3K |
| Earning Date | 03-02-2026 | 05-21-2026 |
| Dividend Yield | ★ 2.43% | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | ★ 4.74 | 0.04 |
| Revenue | ★ $10,396,618.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $2.53 | $64.50 |
| Revenue Growth | ★ 6.79 | N/A |
| 52 Week Low | $9.47 | $1.35 |
| 52 Week High | $14.52 | $3.55 |
| Indicator | MDRR | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 47.67 | 52.40 |
| Support Level | $11.01 | $1.49 |
| Resistance Level | $12.23 | $2.88 |
| Average True Range (ATR) | 0.35 | 0.22 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 23.68 | 14.19 |
Medalist Diversified Inc owns ten investment properties comprised of three retail properties, three flex/industrial properties, and four STNL properties, including the Tesla Pensacola Property. Through its subsidiary, the company sponsors Delaware Statutory Trusts (DSTs) that provide accredited investors access to institutional-quality real estate with the transparency and governance of a public company. The company has three reportable segments, consisting of retail center properties, flex center properties, and STNL properties. The company generates the majority of its revenue from the Retail Center Property.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.